Interstitial Lung Disease Clinical Trials

Scientists in the Duke Division of Pulmonary, Allergy, and Critical Care Medicine are striving to improve our understanding of the molecular mechanisms leading to interstitial lung disease (ILD).

Currently, Duke is collaborating on research to investigate the biologic and genetic basis of idiopathic pulmonary fibrosis. The ILD Clinic at Duke is participating in several multi-center clinical trials to test new and promising medications for treatment of IPF.

Current Clinical Trials

Each study has specific pulmonary function, radiographic, pathologic, and disease history requirements. A surgical lung biopsy is often not required.

Inclusion criteria vary among the studies, but all require a confident diagnosis of IPF (rather than other interstitial lung diseases, such as those associated with connective tissue disorders).

Similarly, exclusion criteria vary among studies. Of particular relevance, a significant amount of either radiographic emphysema or frank airways’ obstruction will preclude patients from participating.

Select a trial to read the full description on the Web site:

Medi 1066 (MedImmune)
A Phase II, randomized dose-ranging study to evaluate the efficacy of Tralokinumab in adults with Idiopathic Pulmonary Fibrosis.
Patients will be randomized in a 1:1:1 ratio to one of two doses of IV tralokinumab (400 or 800 mg) or placebo every 4 weeks for 68 weeks for a total of 18 doses. A follow-up period of four more visits over 16 weeks will occur.
— Primary Investigator: Lake Morrison, MD

RAINIER (Gilead)
A Phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of GS-6624 in subjects with Idiopathic Pulmonary Fibrosis.
Patients will be randomized in a 1:1 ratio to receive either GS-6624 or placebo for up to 182 weeks and involve 32 visits.
— Primary Investigator: Lake Morrison, MD

For additional information contact Rose Marie Smigla, Clinical Research Coordinator, at 919-681-3866.

Enroll in a Pulmonary Clinical Trial at Duke

Researchers in our division are investigating a variety of treatments and therapies to respond to lung disease. For a list of current pulmonary-related clinical trials, visit

end fo content area